October 18, 2019

Mayo breast cancer vaccine could be available in less than a decade

By Karl W Oestreich

Forbes
by Robin Seaton Jefferson

Researchers at Mayo Clinic in Jacksonville, Florida say a vaccine they have developed could be available within eight years that may not only stop the recurrence of breast and ovarian cancers, but prevent them from developing in the first place. “It is reasonable to say that we could have a vaccine within eight years that may be available to patients through their pharmacy or their doctor,” said. Mayo Clinic investigator, Keith L. Knutson, Ph.D. in an interview today. Knutson said the research is in its early phases, and it will be at least three years before a phase 3 trial of Mayo Clinic’s cancer vaccine would be available to large numbers of patients.

Forbes magazine logo

Reach: Forbes magazine focuses on business and financial news with core topics that include business, technology, stock markets, personal finance, and lifestyle. The magazine is published twice each month and has more than 826,000 subscribers. Forbes Online receives more than 29.7 million unique visitors each month.

Additional coverage: People, New York PostCBS Atlanta, CBS Chicago, Classic Rock 96.1, FOX 13, Washington Times, CBS Pittsburgh, Infobae, The Sun, 10 TV, Unilad, CBS Denver, FOX 2 Detroit, Becker’s Hospital Review, Big Think, WPLG Local 10, KXLY Spokane, FOX 5 Atlanta, KNUE-Radio, FOX 13 Tampa Bay, FOX 35 Orlando, FOX 32 Chicago, WTHR 13, FOX News, Prevention, AOL, Yahoo! Sports, Cosmopolitan, FOX 5 New York

Previous coverage:
First Coast News, Clinical trials for new cancer vaccine at Mayo Clinic show promising results

Context: Keith Knutson, Ph.D. is the principal investigator of a $13.3 million, five-year Breakthrough Award grant from the Department of Defense to test a vaccine designed to prevent the recurrence of triple-negative breast cancer, a subset of breast cancer for which there are no targeted therapies. In addition to his research, Dr. Knutson participates in and chairs several study sections, is co-director of the Mayo Clinic Immune Monitoring Core and director of the Mayo Clinic Ovarian Cancer Immunotherapy Program.

Contact: Tia Ford

Tags: breast cancer vaccine, clinical trials, Dr. Keith Knutson, Forbes, Uncategorized

Contact Us · Privacy Policy